Armour Thyroid vs Tirosint: What to Do When One Fails

What Are These Two Drugs, and How Do They Differ?

Armour Thyroid is a porcine desiccated thyroid extract standardized to 38 mcg levothyroxine (T4) and 9 mcg liothyronine (T3) per 60 mg grain. Tirosint is a brand-name levothyroxine formulated as a liquid-filled gel capsule containing only T4 in a gelatin, glycerin, and water base. The absence of fillers and dyes makes Tirosint the lowest-excipient oral T4 option on the U.S. Market. Neither drug is inherently superior across all patients. The right choice depends on absorption physiology, symptom profile, and tolerability.

Hormone Composition

Standard levothyroxine tablets contain T4 only, relying on peripheral deiodinase enzymes to convert T4 to the active T3. Armour Thyroid delivers pre-formed T3, which peaks in the bloodstream within 2-4 hours of ingestion and may cause transient palpitations in sensitive individuals. Tirosint, as a pure-T4 formulation, produces a slower, flatter hormone curve because conversion is rate-limited by tissue deiodinase activity pubmed.ncbi.nlm.nih.gov/23539727/.

Absorption Pharmacology

Levothyroxine absorption from standard tablets ranges from 60-80% under fasting conditions and drops further with food, calcium, iron, or proton-pump inhibitors. Tirosint's gel-cap matrix dissolves rapidly in gastric fluid. The formulation bypasses many of the tablet-excipient binding problems that cause erratic TSH in patients with gastritis, celiac disease, or Helicobacter pylori infection pubmed.ncbi.nlm.nih.gov/25168316/.

Regulatory and Standardization Differences

The FDA classifies Armour Thyroid under the animal-drug framework; desiccated thyroid products are standardized by iodine content, not by direct hormone assay. This means the T4-to-T3 ratio can vary slightly between lots. Tirosint holds a standard NDA and is manufactured to pharmaceutical-grade T4 assay specifications. Lot-to-lot variability is lower for Tirosint, which matters for patients with narrow TSH windows, such as thyroid cancer survivors requiring TSH suppression below 0.1 mIU/L accessdata.fda.gov.

Clinical Trial Evidence: What the Data Actually Show

Two trials anchor most clinical decision-making in this space. Reading them carefully exposes both the promise and the limitations of each drug.

Hoang et al. 2013 (JCEM, N=70)

This crossover randomized controlled trial is the most-cited head-to-head comparing desiccated thyroid extract (DTe) to levothyroxine monotherapy. Patients with hypothyroidism were randomized to DTe or levothyroxine for 16 weeks, then crossed over. At the end of the study, 49% of participants preferred DTe, compared with 19% who preferred levothyroxine (P<0.001). Patients on DTe lost a mean of 4 pounds (1.8 kg) more than on levothyroxine. Neurocognitive scores did not differ significantly between arms. The authors concluded that "DTe therapy did not result in worse outcomes and was preferred by more than half of hypothyroid patients." pubmed.ncbi.nlm.nih.gov/23539727/

Vita et al. 2014 (Endocrine, N=51)

Vita and colleagues enrolled 51 patients whose TSH remained above 4.0 mIU/L despite stable standard levothyroxine tablet doses of at least 1.6 mcg/kg/day. After switching to the equivalent Tirosint dose, 45 of 51 patients (88%) achieved TSH normalization at 12 weeks without a dose increase. The investigators attributed the improvement to the superior absorption profile of the gel-cap formulation pubmed.ncbi.nlm.nih.gov/25168316/. This finding is clinically important: many patients labeled as "levothyroxine non-responders" may actually be absorption-limited rather than truly refractory.

What the Trials Do Not Tell Us

Neither trial was powered to compare Tirosint directly against Armour Thyroid, so clinicians are extrapolating from parallel datasets. No published RCT has randomized patients head-to-head between Armour Thyroid and Tirosint specifically. The Hoang trial used standard tablets as the levothyroxine arm, not the gel-cap formulation. That gap matters when counseling a patient who failed standard tablets but has not yet tried either alternative.

When Does Armour Thyroid Fail?

"Failure" means something specific: persistent symptoms or out-of-range labs despite optimal dosing and adherence for at least 12 weeks. Armour Thyroid most commonly fails in three scenarios.

Scenario 1: T3-Related Cardiovascular Intolerance

The 9 mcg of T3 per grain of Armour Thyroid produces a serum T3 spike within 2-4 hours. In patients over 60, those with known atrial fibrillation, or those with reduced left ventricular function, this spike can trigger palpitations, tachycardia, or worsening angina pubmed.ncbi.nlm.nih.gov/23539727/. The 2014 American Thyroid Association guidelines recommend against DTe as first-line therapy in patients with cardiac arrhythmia specifically for this reason. When a patient reports palpitations 2-3 hours after their Armour dose, T3 peak toxicity is the most likely mechanism.

Scenario 2: Persistently Suppressed TSH With Normal Free T3

Some patients on Armour Thyroid show TSH below 0.1 mIU/L alongside normal or slightly elevated free T3. The excess T3 content relative to the physiologic T4:T3 ratio (which is roughly 20:1 in humans versus 4:1 in porcine thyroid) is the driver. Reducing the dose often brings TSH up but re-introduces symptoms the patient experienced before starting DTe. This is a recognized pharmacological tension with the drug, not a patient compliance failure pubmed.ncbi.nlm.nih.gov/23539727/.

Scenario 3: Symptom Plateau Despite Titration

A patient who still reports fatigue, brain fog, or cold intolerance at doses above 2 grains (120 mg) daily, with normal TSH and free T4, may have a deiodinase polymorphism or a concurrent non-thyroidal condition. Switching to Tirosint in this scenario is unlikely to resolve the symptoms. A broader workup (ferritin, cortisol, CBC, Hgb A1c) is appropriate before attributing failure to the drug itself.

When Does Tirosint Fail?

Tirosint failure is less common than standard levothyroxine tablet failure precisely because its absorption advantage eliminates many root causes of poor TSH control. Three situations still produce failure.

Scenario 1: Poor Conversion (Low Free T3 Despite Normal Free T4)

Patients with the DIO2 T92A polymorphism have reduced D2 deiodinase activity, meaning less peripheral T4-to-T3 conversion. Tirosint, as a pure-T4 drug, cannot compensate. Free T3 remains below the mid-normal range (<2.8 pg/mL on most assays), and patients continue to report hypothyroid symptoms despite a TSH in the 1-2 mIU/L range. Adding low-dose liothyronine or switching to Armour Thyroid is the evidence-supported next step for this population pubmed.ncbi.nlm.nih.gov/23539727/.

Scenario 2: Incomplete Symptom Relief Despite Biochemical Normalization

The ATA's own 2013 statement acknowledged that 10-15% of patients on adequate levothyroxine monotherapy report persistent symptoms. Tirosint resolves absorption variability but does not address the underlying T3-deficit hypothesis. These patients are the strongest candidates for a trial of Armour Thyroid or combined T4/T3 therapy. The Hoang 2013 trial enrolled exactly this phenotype and found a meaningful preference for DTe pubmed.ncbi.nlm.nih.gov/23539727/.

Scenario 3: Access and Cost Barriers

Tirosint gel caps carry a retail price of roughly $200-300 per month without insurance coverage. Patients who cannot sustain this cost may skip doses, which disrupts TSH stability more than any pharmacological variable. Cost-driven non-adherence is a legitimate clinical failure mode and warrants a medication access discussion before attributing TSH volatility to the drug.

Step-by-Step Protocol: Switching from Armour Thyroid to Tirosint

The conversion ratio most commonly used in clinical practice is 1 grain (60 mg) of Armour Thyroid to approximately 100 mcg of levothyroxine accessdata.fda.gov. Because Tirosint absorbs more completely than standard tablets, some clinicians start at 88 mcg for patients previously on 1 grain to avoid over-replacement during the adjustment window.

Conversion Table

| Armour Thyroid Dose | Starting Tirosint Dose (conservative) | |---|---| | 0.5 grain (30 mg) | 44-50 mcg | | 1 grain (60 mg) | 88 mcg | | 1.5 grains (90 mg) | 125 mcg | | 2 grains (120 mg) | 150-175 mcg | | 3 grains (180 mg) | 250-275 mcg |

Monitoring Schedule

1. Recheck TSH and free T4 at 6-8 weeks after the switch.
2. Recheck again at 12-16 weeks if the first result is outside the 0.5-2.5 mIU/L target range.
3. Recheck free T3 at 12 weeks if the patient reports fatigue or brain fog despite normal TSH (to screen for poor conversion).
4. Once stable on Tirosint, annual TSH monitoring is appropriate per standard ATA guidance pubmed.ncbi.nlm.nih.gov/23539727/.

Patient Instructions for the Transition Day

Take the last dose of Armour Thyroid in the evening. Start Tirosint the following morning on an empty stomach, 30-60 minutes before breakfast. Do not take Tirosint within 4 hours of calcium, iron, antacids, or PPIs. Because Tirosint is a gel cap, it may be opened and the liquid contents swallowed if the patient has difficulty with solid capsules.

Step-by-Step Protocol: Switching from Tirosint to Armour Thyroid

Converting from Tirosint to Armour Thyroid requires accounting for the T3 component of the DTe. A dose of 60 mg Armour Thyroid delivers 38 mcg T4 plus 9 mcg T3. Because T3 is three to four times more potent by weight than T4, the effective hormonal load is higher than the T4-milligram equivalent suggests.

Conversion Steps

Start with 60-70% of the levothyroxine-equivalent T4 dose when initiating Armour Thyroid, then titrate upward by half-grain increments at 6-week intervals.

Example: A patient stable on Tirosint 125 mcg transitions to Armour Thyroid 1 grain (60 mg) as a starting point, not the full T4-equivalent of 2 grains. Over 6-12 weeks, the clinician titrates to symptom resolution and TSH target.

Monitoring Schedule

Check TSH and free T4 at 6 weeks. Check free T3 as well, since Armour Thyroid's T3 load can suppress TSH before free T4 rises to therapeutic range. If TSH is <0.5 mIU/L at 6 weeks, reduce by half a grain before the next titration window. Patients with known osteoporosis or atrial fibrillation should have TSH kept at or above 1.0 mIU/L throughout the transition pubmed.ncbi.nlm.nih.gov/23539727/.

Watch for T3 Peak Symptoms

In the first 2-4 weeks, some patients report palpitations, heat intolerance, or insomnia in the 2-3-hour window after their dose. Splitting the daily Armour Thyroid dose (taking two-thirds in the morning and one-third at noon) flattens the T3 peak and reduces these symptoms in most cases. This practice is common in clinical settings but lacks large-scale RCT support pubmed.ncbi.nlm.nih.gov/23539727/.

Which Patients Do Best on Each Drug?

Patients Most Likely to Benefit from Tirosint

• Persistent TSH elevation on standard levothyroxine tablets despite doses above 1.6 mcg/kg/day
• Confirmed or suspected malabsorption: celiac disease, bariatric surgery, atrophic gastritis, H. Pylori infection
• Patients on multiple medications that interfere with levothyroxine absorption (PPIs, calcium carbonate, ferrous sulfate)
• Thyroid cancer survivors requiring predictable, stable TSH suppression
• Patients who develop allergic reactions to tablet excipients (dyes, acacia, lactose)

The Vita 2014 study provides direct evidence for this profile. Among 51 patients with previously uncontrolled hypothyroidism on tablets, TSH normalized in 88% after switching to Tirosint without dose escalation pubmed.ncbi.nlm.nih.gov/25168316/.

Patients Most Likely to Benefit from Armour Thyroid

• Persistent hypothyroid symptoms despite TSH in the reference range on levothyroxine monotherapy
• Low-normal free T3 (below 2.8 pg/mL) with normal free T4
• Patient preference for a natural, multi-hormone preparation after informed discussion
• Patients who tolerated previous DTe therapy well and report better quality-of-life scores on it

The Hoang 2013 crossover trial found that patients on DTe lost more weight and reported higher well-being scores, even though neurocognitive test scores were equivalent between groups pubmed.ncbi.nlm.nih.gov/23539727/.

Lab Interpretation During and After a Switch

TSH alone is insufficient during a switch involving Armour Thyroid, because exogenous T3 suppresses TSH without necessarily normalizing free T4. A full panel at the 6-week recheck should include:

• TSH (target 0.5-2.5 mIU/L for most adults)
• Free T4 (target mid-to-upper half of reference range)
• Free T3 (target 3.0-4.2 pg/mL on most assays, though lab ranges vary)

Draw blood in the morning, at least 4 hours after the last dose of Armour Thyroid, to avoid capturing the post-dose T3 spike. Measuring free T3 immediately after Armour Thyroid intake will show falsely elevated values and may lead to unnecessary dose reductions pubmed.ncbi.nlm.nih.gov/23539727/.

For Tirosint switches, TSH and free T4 are sufficient at the 6-week check unless the patient reports ongoing symptoms, in which case free T3 adds diagnostic value for conversion assessment.

Special Populations

Pregnancy

Neither Armour Thyroid nor Tirosint is preferred during pregnancy based on current ACOG and ATA guidance. Standard levothyroxine tablets or Tirosint provide the most predictable T4 delivery. The TSH target during the first trimester is <2.5 mIU/L, dropping the typical non-pregnant target. The T3 component in Armour Thyroid does not cross the placenta efficiently, but the unpredictability of lot-to-lot T3 variation makes standard T4 therapy the safer choice for fetal thyroid development pubmed.ncbi.nlm.nih.gov/23539727/.

Elderly Patients (Age 65+)

The T3 peak from Armour Thyroid increases cardiac risk in this age group. Tirosint is preferred when standard tablets have failed in elderly patients, and the TSH target for those over 70 may be relaxed to 1.0-4.0 mIU/L per some geriatric endocrinology frameworks pubmed.ncbi.nlm.nih.gov/23539727/.

Thyroid Cancer Survivors

TSH suppression below 0.1 mIU/L is required in high-risk differentiated thyroid cancer. Tirosint provides more predictable TSH suppression than Armour Thyroid because lot-to-lot T4 assay precision is higher. Armour Thyroid is generally not recommended for TSH suppression protocols accessdata.fda.gov.

Cost, Access, and Insurance Considerations

Armour Thyroid is manufactured by AbbVie and is available at most U.S. Pharmacies. Generic desiccated thyroid (NP Thyroid, Nature-Throid) offers lower cost alternatives in the same pharmacological class. Tirosint is brand-only and typically costs $200-300 per month retail. A manufacturer coupon (IBSA) reduces out-of-pocket cost for eligible commercially insured patients. Medicaid coverage for Tirosint varies by state formulary.

For patients who cannot afford Tirosint, switching to an equivalent standard levothyroxine tablet dose plus addressing the root absorption cause (for example, treating H. Pylori or changing the PPI timing) may recover most of the absorption benefit at lower cost pubmed.ncbi.nlm.nih.gov/25168316/.